Pharmaceuticals

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

* ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncology inthe United States * The Phase I PERFORM trial, ongoing at four major U.S. cancer centers, is evaluating the safety and preliminary efficacy of ATN-031 in patients with advanced solid tumor...

2024-03-20 20:30 2074

Innovent Announces 2023 Annual Results and Business Updates

A transformative year of strong performance and material innovation progress ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...

2024-03-20 19:44 2876

BGI Group Celebrates 20th Anniversary of Partnerships in Healthcare and Genomics in Thailand

BANGKOK, March 20, 2024 /PRNewswire/ -- This year marks the twentieth anniversary of BGI Group's close relationship with the Kingdom ofThailand. Initially both parties were brought together through an international humanitarian rescue effort during the Indian Ocean tsunami where BGI worked with ...

2024-03-20 12:39 1646

Docquity enables Italian biopharmaceutical company Menarini to double HCP reach and engagement in Malaysia

* A Docquity client since 2021, Menarini Malaysia further engaged the platform to raise awareness among target HCPs on multimodal approaches to post-surgery pain management and recovery * Docquity's Awareness to Advocacy (A2A) Program, backed by its in-depth HCP network insights, droveMenarini...

2024-03-20 10:00 1404

Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients

SHANGHAI, March 20, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Singapore Health Sciences ...

2024-03-20 09:16 1343

Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research

SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in he...

2024-03-20 08:30 1435

Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure

ST. GALLEN, SWITZERLAND, March 19, 2024 /PRNewswire/ -- CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations ...

2024-03-19 19:09 1940

Cognizant to apply generative AI to enhance drug discovery for pharmaceutical clients with NVIDIA BioNeMo

Cognizant's AI and industry expertise, combined with the NVIDIA BioNeMo generative AI platform, create a strong foundation to improve outcomes in the healthcare and life sciences sectors TEANECK, N.J., March 19, 2024 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) is advancing the application of genera...

2024-03-19 12:01 2054

Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)

ROCKVILLIE, Md. and SUZHOU, China, March 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major d...

2024-03-19 08:00 1491

Cambrex Nears Completion of 5-year, $100-Million-Dollar Investment Plan, One Year Ahead of Schedule

EAST RUTHERFORD, N.J., March 18, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it is nearing the completion of a 5-year,$100-million-dollar investment strategy, one year ahead of schedule. The project, which adds mo...

2024-03-18 18:00 1428

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

SHANGHAI, March 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened i...

2024-03-18 09:00 1536

/C O R R E C T I O N -- Sisram Medical Ltd/

In the news release, Sisram Medical to Report FY2023 Financial Results on March 20 and Hold a Conference Call on March 21, issued on 14-Mar-2024 by Sisram Medical Ltd over PR Newswire, we are advised by the company that regarding the time, specifically, the Israel Time, should read "2:00 p.m." ra...

2024-03-15 16:42 2600

Novartis expands its biopharmaceutical manufacturing site in Singapore

* Invests US$256 million to expand biopharmaceutical manufacturing facility in Singapore, addressing the soaring demand in the Asian market  * Set to generate 100 high skilled employment opportunities in Singapore's life science industry  SINGAPORE, March 15, 2024 /PRNewswire/ -- Novartis today...

2024-03-15 14:55 3196

Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024

JINAN, China, March 15, 2024 /PRNewswire/ -- On 8 March local time, during the 25th European Society of Gynecological Oncology (ESGO) Conference (ESGO 2024) in Spain, Qilu Pharmaceutical unveiled the Phase II clinical trial results for iparomlimab and tuvonralimab (QL1706) in an oral presentation....

2024-03-15 14:07 2128

Seegene and Springer Nature Announce Awardees for the Open Innovation Program

* 26 submissions selected from a total of 281 applications from 47 countries to diagnose infectious and vector-borne diseases * Awardees representing 12 countries in Europe, the Americas, Asia and Africa , will receive research grants of up toUSD 600,000 per project * As part of the Seegene's...

2024-03-15 13:41 2059

CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. * This marks the 13th NDA approval obtained by CStone and sugemalimab's fifth indication approved inChina, following stage III and IV no...

2024-03-15 12:10 2061

Alphamab Oncology to Present Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors at AACR 2024

SUZHOU, China, March 14, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from phase I clinical study conducted inAustralia (JSKN003-101) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, has b...

2024-03-14 08:39 1589

Hummingbird Bioscience and Dartmouth's Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024

SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience andDartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually onWednesday, March 27, 2024 ( 11:00 AM - 3:30 PM ET). VISTA is a novel immune checkpoint imp...

2024-03-13 17:00 2173

Novel Molecules From Generative AI to Phase II: First Novel TNIK Inhibitors for Fibrotic Diseases Discovered and Designed Using Generative AI

* A study published in Nature Biotechnology presents the entire journey of INS018_055, from AI algorithms to Phase II clinical trials for the first time. * Raw data from 13 preclinical experiments and 3 clinical trials referenced in this study can be accessed by visiting Insilico'sdata room <...

2024-03-13 08:00 2112

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

SAN DIEGO and TOKYO and WETTEREN, Belgium, March 12, 2024 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Leadership Awards in all six categories - Capabilities, Compatibility,...

2024-03-12 20:00 1704
12345 ... 180

Week's Top Stories